Clinical Trials
26 trialsNCT07428707 2026-06-04
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Recruiting
NCT06973187 2026-06-03
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3 Recruiting
NCT04623541 2026-06-02
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT07218341 2026-05-22
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 4 Recruiting
NCT06588478 2026-05-19
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 2 Recruiting
NCT07342478 2026-05-14
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
Phase 3 Recruiting
NCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05254743 2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT07162181 2026-04-17
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07516093 2026-04-08
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Nurix Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06876649 2026-03-02
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
Phase 4 Recruiting
NCT06876662 2026-03-02
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4 Recruiting
NCT06466122 2026-02-19
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05677919 2026-02-12
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 2 Active not recruiting
NCT04849416 2026-02-06
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
Phase 2 Completed
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT05023980 2026-01-22
BRUIN CLL-313
Eli Lilly and Company
Phase 3 Active not recruiting
NCT06333262 2026-01-21
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06043674 2026-01-07
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05317936 2025-12-15
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06967610 2025-11-06
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06812715 2025-08-06
PIPOZA
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT06839872 2025-06-05
BOSS
AstraZeneca
Phase 2 Withdrawn